Drug intelligence / Profile preview

AT-301 (A28 Therapeutics)

Development stage: Preclinical
Lead developer: A28 Therapeutics
Modality: Peptides
Administration: Oral

Overview

AT-301 is a targeted oncolytic peptide being developed by A28 Therapeutics for the treatment of ovarian cancer. It is designed to selectively target cancer cells expressing the Follicle-Stimulating Hormone Receptor (FSHR). The drug consists of an FSHR-targeting moiety linked to an oncolytic peptide payload. Upon binding to FSHR on the surface of cancer cells, the peptide induces selective cell death (oncolysis). This approach aims to minimize off-target toxicity by focusing the cytotoxic effect on FSHR-positive malignant tissues.

Targets

FSHR (Follicle-stimulating hormone receptor)

Beyond the preview

Go deeper on AT-301 (A28 Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-301 (A28 Therapeutics).

Explore the full profile